Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2020

25.03.2020 | Original Article

The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis

verfasst von: Jia-Yong Liu, Bao-Rang Zhu, Yu-Dong Wang, Xin Sun

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to investigate the efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.

Methods

Designed as a retrospective study, a total of 105 metastatic osteosarcoma patients who progressed after standard therapy were included in this study. The metastatic osteosarcoma patients received 500–750 mg Apatinib mesylate according to body surface area until disease progression or unacceptable toxicity with 28 days one cycle. Overall response was evaluated after two cycles Apatinib treatment, then progression-free survival (PFS) and overall survival (OS) were evaluated, and safety data were recorded. Additionally. peripheral blood and peripheral blood mononuclear cell (PBMC) specimens in the osteosarcoma patients were collected for the genotyping of VEGFR2 genetic variation and mRNA expression, respectively. Analysis on the association between genotype and baseline characteristics and VEGFR2 gene mRNA expression was analyzed. The univariate analysis of genotypes and prognosis was carried out by Kaplan–Meier survival analysis, and multivariate analysis was adjusted by Cox regression analysis.

Results

The objective response rate (ORR) of the 105 metastatic osteosarcoma patients was 37.14%, disease control rate (DCR) was 77.14%, median PFS was 4.1 months, and median OS was 9.0 months. Regarding the VEGFR2 gene polymorphisms analysis, only − 906 T > C was of clinical significance. The prevalence of − 906 T > C in VEGFR2 among the study population was as follows: TT genotype 62 cases (59.05%), TC genotype 36 cases (34.29%) and CC genotype 7 cases (6.66%), minor allele frequency of − 906 T > C was 0.24. Compared with patients with TC/CC genotype, patients with TT genotype showed longer median PFS (5.0 versus 3.1 months, P = 0.011) and median OS (9.8 versus 7.6 months, P = 0.032). There was no correlation between the polymorphism and adverse reactions. Additionally, the mRNA expression in 69 randomly selected sample indicated that the mRNA expression of VEGFR2 of the patients with CC/TC genotypes were significantly higher than those of the TT genotype patients (P < 0.001).

Conclusion

Apatinib was safe and effective in the treatment of metastatic osteosarcoma patients who progressed after standard therapy. The clinical outcomes of Apatinib may be influenced by the polymorphism − 906 T > C of VEGFR2 through mediating the mRNA expression of VEGFR2.
Literatur
1.
Zurück zum Zitat Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132PubMedCrossRef Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132PubMedCrossRef
2.
Zurück zum Zitat Tirtei E, Asaftei SD, Manicone R et al (2018) Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori 104:202–206PubMedCrossRef Tirtei E, Asaftei SD, Manicone R et al (2018) Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori 104:202–206PubMedCrossRef
3.
Zurück zum Zitat Zhang T, Zhang S, Yang F et al (2018) Efficacy comparison of six chemotherapeutic combinations for osteosarcoma and ewing's sarcoma treatment: a network meta-analysis. J Cell Biochem 119:250–259PubMedCrossRef Zhang T, Zhang S, Yang F et al (2018) Efficacy comparison of six chemotherapeutic combinations for osteosarcoma and ewing's sarcoma treatment: a network meta-analysis. J Cell Biochem 119:250–259PubMedCrossRef
4.
Zurück zum Zitat Davis LE, Bolejack V, Ryan CW et al (2019) Randomized double-blind Phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol 37:1424–1431PubMedCrossRefPubMedCentral Davis LE, Bolejack V, Ryan CW et al (2019) Randomized double-blind Phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol 37:1424–1431PubMedCrossRefPubMedCentral
5.
Zurück zum Zitat Lagmay JP, Krailo MD, Dang H et al (2016) Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: learning from the past to move forward. J Clin Oncol 34:3031–3038PubMedPubMedCentralCrossRef Lagmay JP, Krailo MD, Dang H et al (2016) Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: learning from the past to move forward. J Clin Oncol 34:3031–3038PubMedPubMedCentralCrossRef
6.
7.
Zurück zum Zitat Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23:508–516PubMedCrossRef Grignani G, Palmerini E, Dileo P et al (2012) A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 23:508–516PubMedCrossRef
8.
9.
Zurück zum Zitat Duffaud F, Mir O, Boudou-Rouquette P et al (2019) Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120–133PubMedCrossRef Duffaud F, Mir O, Boudou-Rouquette P et al (2019) Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120–133PubMedCrossRef
10.
Zurück zum Zitat Fioramonti M, Fausti V, Pantano F et al (2018) Cabozantinib affects osteosarcoma growth through a direct effect on tumor cells and modifications in bone microenvironment. Sci Rep 8:4177PubMedPubMedCentralCrossRef Fioramonti M, Fausti V, Pantano F et al (2018) Cabozantinib affects osteosarcoma growth through a direct effect on tumor cells and modifications in bone microenvironment. Sci Rep 8:4177PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Li J, Qin S, Xu J et al (2016) Randomized, double-blind, placebo-controlled Phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 34:1448–1454PubMedCrossRef Li J, Qin S, Xu J et al (2016) Randomized, double-blind, placebo-controlled Phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol 34:1448–1454PubMedCrossRef
12.
Zurück zum Zitat Liu K, Ren T, Huang Y et al (2017) Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis 8:e3015PubMedPubMedCentralCrossRef Liu K, Ren T, Huang Y et al (2017) Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis 8:e3015PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Zheng B, Ren T, Huang Y et al (2018) Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun 495:1695–1701PubMedCrossRef Zheng B, Ren T, Huang Y et al (2018) Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun 495:1695–1701PubMedCrossRef
14.
Zurück zum Zitat Xie L, Xu J, Sun X et al (2019) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label Phase II clinical trial. Oncologist 24:e542–e550PubMed Xie L, Xu J, Sun X et al (2019) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label Phase II clinical trial. Oncologist 24:e542–e550PubMed
15.
Zurück zum Zitat Liao Z, Li F, Zhang C et al (2019) Phase II trial of VEGFR2 inhibitor Apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med 51:24PubMedCentralCrossRef Liao Z, Li F, Zhang C et al (2019) Phase II trial of VEGFR2 inhibitor Apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med 51:24PubMedCentralCrossRef
16.
17.
Zurück zum Zitat Tang L, Yu W, Wang Y et al (2019) Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol 21:1624–1633PubMedCrossRef Tang L, Yu W, Wang Y et al (2019) Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol 21:1624–1633PubMedCrossRef
18.
Zurück zum Zitat Liu X, Qin S, Wang Z et al (2018) Correction to: early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 11:5PubMedPubMedCentralCrossRef Liu X, Qin S, Wang Z et al (2018) Correction to: early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 11:5PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Liu S, Wu M, Zhang B et al (2019) Analysis of genetic polymorphisms for age-related macular degeneration (AMD) in Chinese Tujia ethnic minority group. BMC Med Genet 20:25PubMedPubMedCentralCrossRef Liu S, Wu M, Zhang B et al (2019) Analysis of genetic polymorphisms for age-related macular degeneration (AMD) in Chinese Tujia ethnic minority group. BMC Med Genet 20:25PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Babyshkina N, Zavyalova M, Tarabanovskaya N et al (2018) Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem 444:197–206PubMedCrossRef Babyshkina N, Zavyalova M, Tarabanovskaya N et al (2018) Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem 444:197–206PubMedCrossRef
21.
Zurück zum Zitat Escudier B, Rini BI, Motzer RJ et al (2015) Genotype correlations with blood pressure and efficacy from a randomized Phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer 13:328–337.e323PubMedCrossRef Escudier B, Rini BI, Motzer RJ et al (2015) Genotype correlations with blood pressure and efficacy from a randomized Phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer 13:328–337.e323PubMedCrossRef
22.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
23.
Zurück zum Zitat Miller TP, Fisher BT, Getz KD et al (2019) Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer 66:e27747PubMedCrossRefPubMedCentral Miller TP, Fisher BT, Getz KD et al (2019) Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer 66:e27747PubMedCrossRefPubMedCentral
24.
Zurück zum Zitat Tian Z, Gu Z, Wang X et al (2019) Efficacy and safety of Apatinib in treatment of osteosarcoma after failed standard multimodal therapy: an observational study. Medicine (Baltimore) 98:e15650CrossRef Tian Z, Gu Z, Wang X et al (2019) Efficacy and safety of Apatinib in treatment of osteosarcoma after failed standard multimodal therapy: an observational study. Medicine (Baltimore) 98:e15650CrossRef
25.
26.
Zurück zum Zitat Chen LT, Oh DY, Ryu MH et al (2017) Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat 49:851–868PubMedPubMedCentralCrossRef Chen LT, Oh DY, Ryu MH et al (2017) Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat 49:851–868PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Liu X, Qin S, Wang Z et al (2017) Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 10:153PubMedPubMedCentralCrossRef Liu X, Qin S, Wang Z et al (2017) Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol 10:153PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Fang SC, Huang W, Zhang YM et al (2019) Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with Apatinib. Onco Targets Ther 12:985–992PubMedPubMedCentralCrossRef Fang SC, Huang W, Zhang YM et al (2019) Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with Apatinib. Onco Targets Ther 12:985–992PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Wei JH, Feng ZH, Cao Y et al (2019) Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study. Lancet Oncol 20:591–600PubMedCrossRef Wei JH, Feng ZH, Cao Y et al (2019) Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study. Lancet Oncol 20:591–600PubMedCrossRef
30.
Zurück zum Zitat Agemi Y, Shimokawa T, Sasaki J et al (2019) Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS ONE 14:e0210499PubMedPubMedCentralCrossRef Agemi Y, Shimokawa T, Sasaki J et al (2019) Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS ONE 14:e0210499PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Zhu B, Li J, Xie Q et al (2018) Efficacy and safety of Apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther 19:198–204PubMedPubMedCentralCrossRef Zhu B, Li J, Xie Q et al (2018) Efficacy and safety of Apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther 19:198–204PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Scartozzi M, Faloppi L, Baroni GS et al (2014) VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 135:1247–1256PubMedCrossRef Scartozzi M, Faloppi L, Baroni GS et al (2014) VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 135:1247–1256PubMedCrossRef
33.
Zurück zum Zitat Sullivan I, Riera P, Andres M et al (2019) Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis 22:433–440PubMedCrossRef Sullivan I, Riera P, Andres M et al (2019) Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. Angiogenesis 22:433–440PubMedCrossRef
34.
Zurück zum Zitat George DJ, Martini JF, Staehler M et al (2019) Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis. Clin Cancer Res 25:1165–1173PubMedCrossRef George DJ, Martini JF, Staehler M et al (2019) Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis. Clin Cancer Res 25:1165–1173PubMedCrossRef
35.
Zurück zum Zitat Zhu Y, Feng B, Mei L et al (2019) Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON 24:608–614PubMed Zhu Y, Feng B, Mei L et al (2019) Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON 24:608–614PubMed
36.
Zurück zum Zitat Li J, Jia Y, Gao Y et al (2019) Clinical efficacy and survival analysis of Apatinib combined with docetaxel in advanced esophageal cancer. Onco Targets Ther 12:2577–2583PubMedPubMedCentralCrossRef Li J, Jia Y, Gao Y et al (2019) Clinical efficacy and survival analysis of Apatinib combined with docetaxel in advanced esophageal cancer. Onco Targets Ther 12:2577–2583PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Xie L, Xu J, Sun X et al (2018) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24:e542–e550PubMedPubMedCentral Xie L, Xu J, Sun X et al (2018) Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist 24:e542–e550PubMedPubMedCentral
38.
Zurück zum Zitat Cho HD, Moon KD, Park KH et al (2018) Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol 121:612–621PubMedCrossRef Cho HD, Moon KD, Park KH et al (2018) Effects of auriculasin on vascular endothelial growth factor (VEGF)-induced angiogenesis via regulation of VEGF receptor 2 signaling pathways in vitro and in vivo. Food Chem Toxicol 121:612–621PubMedCrossRef
39.
Zurück zum Zitat Lu Y, Xu Q, Zuo Y et al (2017) Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer 17:875PubMedPubMedCentralCrossRef Lu Y, Xu Q, Zuo Y et al (2017) Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis. BMC Cancer 17:875PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Jinesh GG, Manyam GC, Mmeje CO et al (2017) Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 7:9602PubMedPubMedCentralCrossRef Jinesh GG, Manyam GC, Mmeje CO et al (2017) Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Sci Rep 7:9602PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Ding M, Liu L, Hu C et al (2014) Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res 26:669–677PubMedPubMedCentral Ding M, Liu L, Hu C et al (2014) Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res 26:669–677PubMedPubMedCentral
42.
Zurück zum Zitat Dang YZ, Zhang Y, Li JP et al (2017) High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. Medicine (Baltimore) 96:e5772CrossRef Dang YZ, Zhang Y, Li JP et al (2017) High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. Medicine (Baltimore) 96:e5772CrossRef
Metadaten
Titel
The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
verfasst von
Jia-Yong Liu
Bao-Rang Zhu
Yu-Dong Wang
Xin Sun
Publikationsdatum
25.03.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01644-7

Weitere Artikel der Ausgabe 6/2020

International Journal of Clinical Oncology 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.